Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. - Wikidata - wikimedia - TriplyDB

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

http://www.wikidata.org/entity/Q37269372

about

PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer The Role of PPARs in Cancer The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention Chemotherapy and chemoprevention by thiazolidinediones Chronic Pancreatitis and Pancreatic Cancer 15-Lipoxygenase metabolites of α-linolenic acid, [13-(S)-HPOTrE and 13-(S)-HOTrE], mediate anti-inflammatory effects by inactivating NLRP3 inflammasome.Commonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines Omega-3 Fatty Acids and PPARgamma in Cancer Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma APC-dependent suppression of colon carcinogenesis by PPARgamma Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice Hic-5 regulates an epithelial program mediated by PPARgamma Computational identification and experimental validation of PPRE motifs in NHE1 and MnSOD genes of human.Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer A stochastic model for identifying differential gene pair co-expression patterns in prostate cancer progression.Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells Minireview: Challenges and opportunities in development of PPAR agonists Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy.Oxidized low-density lipoproteins upregulate proline oxidase to initiate ROS-dependent autophagy.In vivo effects of rosiglitazone in a human neuroblastoma xenograft.Effects of eicosapentaenoic acid and docosahexaenoic acid on prostate cancer cell migration and invasion induced by tumor-associated macrophages.Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy.Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load.Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions.Anti-tumor mechanisms of valproate: a novel role for an old drug.A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.The role of adiponectin in cancer: a review of current evidence.Nuclear receptors. I. PPAR gamma in the gastrointestinal tract: gain or pain?Novel insulin sensitizers: pharmacogenomic aspects.Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.Controversy: PPARgamma as a target for treatment of colorectal cancer.A role for the peroxisome proliferator-activated receptor alpha in T-cell physiology and ageing immunobiology.Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism The effect of oxidized low-density lipoprotein combined with adriamycin on the proliferation of Eca-109 cell line.Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells.

P2860

Q21328702-29788FFB-EE5E-4E28-BD2F-1C4F2B46AEF8 Q21342955-D180BA4E-CC70-4F73-B7BC-D46D2BEBE202 Q24601222-4B605A59-5AED-4CDC-822B-5B6763FFCCAF Q27011352-9339FB1C-A550-4BE5-B2F1-534DD6FDEB6B Q27025915-E02AA1DB-B454-4F0E-B46E-26855F042519 Q27316915-875AECD3-7DF6-466E-BAD2-C691501CA7C0 Q28070220-55B54482-A9DD-4266-932C-C34387127C66 Q28238709-55B22120-0A97-4B4A-AD20-42B3BFC22993 Q28292907-DDF44D3A-DC76-414F-BFE3-556C329BA8B9 Q28360358-3F9C27AC-C71F-4635-A4D9-62B0A463E4EA Q28366616-9662B1EB-645B-4964-ACCF-3C65666A3DA8 Q28506424-0E2B5F07-F914-4131-9399-26D70DE38F1A Q28510765-1DFC1C50-2AFF-4CCF-B46D-CE14607E0062 Q28586821-CBC40005-A659-497D-9345-6959EEB8B0AF Q30951265-8DF4E1F6-92D8-4F50-A91C-408288C82B45 Q33215831-A54CBA2D-80DB-4A73-B241-FB30F636226D Q33235601-4CD201CC-4490-40B6-8161-3F103A0C5C42 Q33455595-DC123E7E-48F9-4ADD-ABD7-89D5746CEDDE Q33488343-159C25F1-680F-4CDC-BB88-A84CD096607C Q33563699-FBFE82A7-F9B0-40AB-AE5D-EA676E63F04A Q33631921-BC1411BF-3010-430E-9A9D-6873B14DBA7D Q33637896-607C0450-F4AE-4615-8A0F-8D4E4998874F Q33653171-1A275692-053B-4E4A-AD20-D2F298B5887A Q33705225-C030BC5B-4B9A-4E76-99D8-C4E1F4C6441B Q33723620-C92FAEFC-4E68-4FA4-82E6-8A046D7B274D Q33748699-89BC332B-32B3-4979-8CAB-B08550DB5D24 Q33756414-57CA401A-C95C-414F-97C7-402A5C9898A0 Q33850055-85DB7601-F11E-41EB-A896-1D5ED8C7B4CF Q33874365-07CF7999-86A1-47D0-B3F1-A1C1EA34481C Q34147644-0BD2C76B-C204-4803-AD97-F8398A20C16B Q34262817-1B50E7AC-44F2-43C9-B807-069E1688DC6C Q34271986-193DA4D9-BC15-4818-80B3-9DE96CFA4D24 Q34565656-29D4F17B-9292-4FBD-AACA-FDC630D35C26 Q34609164-C4641986-DB46-4FFB-8199-31ED4F74B94D Q34646050-79BA5E80-27FA-4AE5-B25C-3746E544B26A Q34744898-4FCBAC6F-6F02-42F2-9DE8-639B84E1000F Q34892990-8C12D062-C0B1-4844-AF40-1C536EBC5C56 Q35124419-1BA553F7-9334-4510-9509-5880E9AA4893 Q35147573-31CE7D4A-854E-4FBF-99DF-43F334FA3506 Q35249254-2EA863DD-51AF-4C56-BFCE-F8083896EC05

P2860

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

http://www.wikidata.org/entity/Q37269372

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2000

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effects of ligand activation o ...... amma in human prostate cancer.

@en

Effects of ligand activation o ...... amma in human prostate cancer.

@nl

type

label

Effects of ligand activation o ...... amma in human prostate cancer.

@en

Effects of ligand activation o ...... amma in human prostate cancer.

@nl

prefLabel

Effects of ligand activation o ...... amma in human prostate cancer.

@en

Effects of ligand activation o ...... amma in human prostate cancer.

@nl

P1433

Q37269372-6258F44B-E8A3-4EAE-BDBB-5F74531E1ADE

P1476

Q37269372-216C5E41-7368-41A0-A1D5-F0BB78FCD6E5

P2093

Q37269372-0D43E037-A9B1-4332-A128-F1DD2C4FDAF5

Q37269372-0FE77790-EBA8-46F2-9D74-26A495D05283

Q37269372-34BCA4DB-2608-40DE-AB7D-657F6397790A

Q37269372-3AEB5CF5-241A-456B-8AA1-36BC1D9D7B8A

Q37269372-43234F62-632E-43B3-BD25-E917C6E40F61

Q37269372-48549684-A521-48C3-9C99-6B38E048F42D

Q37269372-79F43519-2495-4219-BCCD-3803237F6461

Q37269372-8218DAFD-D5E2-4549-81D8-F7E6BBD4C27B

Q37269372-974384C2-38BC-4E17-B6C7-F616D6A69A01

Q37269372-9FCA1775-6CC7-4171-9CD1-9C00DCF6F174

P2860

Q37269372-08DCE89F-62C5-41EF-8710-39710EFA6730

Q37269372-29B9AAAD-0C47-4570-BB5A-CBC89498081F

Q37269372-33D820EA-C490-4F53-80F8-D20BC2C4C902

Q37269372-42305A06-AF6D-4363-B02A-C230A379C6D1

Q37269372-7963E815-16A6-4D34-B39D-BEBED7F0305A

Q37269372-8098C02F-2E71-422C-9E2C-11E92B8EDBA0

Q37269372-82AAAA55-F626-4E6C-B15A-BAD267761310

Q37269372-940E2177-060F-414A-9E0B-2EFB83EE271D

Q37269372-9AE29E26-F198-40D8-89B3-3A3A35260CE8

Q37269372-A0DFBB74-EC4B-415E-95A7-EC1123547C08

P304

Q37269372-4525E4CF-D32D-4527-8654-032402A1A74A

P31

Q37269372-9EBC671B-EE87-4D5B-BE95-5E4272F28D95

P356

Q37269372-29E07D7D-326E-4C7F-B164-A03273F0D2DB

P407

Q37269372-9BB688E4-3D07-449B-8C89-E50AEA4FD1A3

P433

Q37269372-C0144444-19A3-44E2-925C-8C1D8C6E6A92

P478

Q37269372-F82E5AC7-8A2D-43F5-A2B7-B5BAE7E3B2A5

P50

Q37269372-D1E392FE-B969-4EF5-AC96-4C635D44FFE9

P577

Q37269372-54B29DA8-886C-4D9D-9D59-F85F132584F4

P5875

Q37269372-CC0818E7-E8D1-416F-A549-5D3269A59086

P698

Q37269372-34587846-4784-4296-90E6-793BE73514CB

P932

Q37269372-8B940FA9-E5E4-423C-9A6C-273E1A428AFA

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Effects of ligand activation o ...... amma in human prostate cancer.

@en

P2093

A Aiyer

http://www.w3.org/2001/XMLSchema#string

B M Spiegelman

http://www.w3.org/2001/XMLSchema#string

C Eng

http://www.w3.org/2001/XMLSchema#string

D S Kaufman

http://www.w3.org/2001/XMLSchema#string

E Mueller

http://www.w3.org/2001/XMLSchema#string

G Demetri

http://www.w3.org/2001/XMLSchema#string

M Smith

http://www.w3.org/2001/XMLSchema#string

P Sarraf

http://www.w3.org/2001/XMLSchema#string

T Kroll

http://www.w3.org/2001/XMLSchema#string

W D Figg

http://www.w3.org/2001/XMLSchema#string

P2860

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation

Activation of mitogen-activated protein kinase associated with prostate cancer progression.

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

P304

10990-10995

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.180329197

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

Philip W. Kantoff

P577

2000-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12336821

http://www.w3.org/2001/XMLSchema#string

P698

10984506

http://www.w3.org/2001/XMLSchema#string

P932

27136

http://www.w3.org/2001/XMLSchema#string